You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives final approval for Diflunisal Tablets

Capital Market 

From USFDA

Zydus Cadila has received final approval from USFDA to market Diflunisal Tablets in the strengths of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Zydus Cadila receives final approval for Diflunisal Tablets

From USFDA

From USFDA

Zydus Cadila has received final approval from USFDA to market Diflunisal Tablets in the strengths of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Zydus Cadila receives final approval for Diflunisal Tablets

From USFDA

Zydus Cadila has received final approval from USFDA to market Diflunisal Tablets in the strengths of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22